Late clinical-stage biopharmaceutical company Vistagen Therapeutics Inc. (VTGN) faces a decisive period as it approaches key Phase 3 readouts for fasedienol, its intranasal candidate for social anxiety disorder.
Topline results from the PALISADE-3 Phase 3 trial of fasedienol, its intranasal candidate for the acute treatment of social anxiety disorder, are expected in the fourth quarter of 2025. A second late-stage study, PALISADE-4, is on track to deliver topline data in the first half of 2026.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com